This review evaluates current and emerging treatments for alopecia areata (AA), covering mild-to-moderate disease (SALT<50) through severe disease (SALT≥50), including JAK inhibitors, topical therapies, immunosuppressants, biologics, and procedural options across patient age groups and comorbidity profiles.
FDA-approved oral JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) have reshaped severe AA management; agent selection is guided by age, safety profile, comorbidities, lab monitoring, and insurance coverage. Switching between JAKis may still yield benefit after nonresponse to one agent.
As a narrative review, it does not perform a systematic synthesis or meta-analysis, limiting quantitative comparison of therapies. Evidence for many adjunctive and procedural modalities (PRP, laser, microneedling) is likely heterogeneous and not graded in detail.
For severe AA (SALT≥50), choose among the three FDA-approved oral JAKis based on patient age, comorbidities, and safety considerations—and consider switching agents after primary nonresponse. For mild-to-moderate AA, start with topical or intralesional corticosteroids ± minoxidil, and use the expanded AASc tool to capture eyebrow/eyelash loss and psychosocial burden beyond scalp SALT score.
Explore related topics